BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.

Total
0
Shares
Related Posts